UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...
Shares in Unity have surged by 36.2% to $29.24 after the company posted higher than expected earnings and unveiled its new ads platform Vector to take on rival AppLovin. At close yesterday, shares had ...
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback